The team worked with male C57BL/6J mice, giving them purified CBD intraperitoneally at 0.2, 10 or 20 milligrams per kilogram of body weight. One group received the compound for just two days, representing short-term or sporadic use, while another group was treated daily for 28 days to mimic chronic exposure. Vehicle-treated controls received the same saline and Tween 80 solution without the active compound. The researchers then measured three classic pro-inflammatory cytokines in plasma, interleukin-1 beta, interleukin-6 and tumour necrosis factor alpha, using ELISA assays, and performed RNA sequencing on the liver and spleen to capture the full transcriptional response in each organ. Sequencing produced an average of 32.4 million raw reads per liver sample, with roughly three quarters of filtered reads uniquely mapped to the mouse reference genome GRCm39.

The cytokine results revealed a striking temporal split. After only two days of treatment, CBD significantly reduced IL-1β across all doses, with concentrations falling from about 69.7 picograms per millilitre in controls to between 49 and 57 picograms per millilitre, an 18 to 30 percent drop. TNF-α fell even harder, declining by roughly 20 to 45 percent in a dose-dependent fashion. IL-6, however, barely moved during this early window. Its decline emerged only during prolonged treatment: by day 14, IL-6 was significantly reduced at every dose, and by day 28 the two higher doses had driven levels down by approximately 40 to 45 percent, from 45.3 to under 29 picograms per millilitre. TNF-α remained suppressed at day 28 as well, suggesting that some anti-inflammatory effects persist while others fade or shift character over time.

The liver, the organ that also handles CBD clearance, turned out to be the epicentre of transcriptional change. Short-term high-dose treatment altered 526 genes, of which nearly 90 percent were upregulated, and enrichment analysis pointed squarely at mitochondrial energy metabolism: oxidative phosphorylation, electron transport chain activity, ATP synthesis and ribosome biogenesis were all prominently represented. The lowest short-term dose affected 116 genes linked to steroid and mineralocorticoid biosynthesis, tissue morphogenesis and lipid transport, while the intermediate dose touched only 11 genes, a reminder that cannabinoids often produce nonlinear, dose-dependent effects. After 28 days, the picture changed again. Long-term treatment altered between 104 and 404 genes depending on dose, with enrichment shifting toward fatty acid and eicosanoid metabolism, arachidonic acid pathways, and, at the highest dose, circadian rhythm regulation including the molecular clock gene Nr1d1, which encodes the nuclear receptor REV-ERBα.

That circadian finding may be one of the most intriguing threads in the study. REV-ERBα is a core component of the cellular clock, and previous work has shown it directly modulates innate immune responses and cytokine production. Immune function in general runs on a diurnal rhythm, with leukocyte trafficking and cytokine secretion varying robustly across the day. The fact that prolonged high-dose CBD enriched circadian and rhythmic process categories, while simultaneously downregulating genes involved in glucocorticoid receptor signalling and responses to nutritional and metabolic stimuli, suggests the compound may be tapping into the deep regulatory circuitry that connects clocks, stress hormones and metabolism rather than merely dampening inflammatory pathways one by one.

Perhaps the most counterintuitive result came at the highest long-term dose, where upregulated liver genes were enriched for innate immune and inflammatory processes, including antimicrobial humoral immunity, interleukin-1-mediated signaling and neutrophil chemotaxis. On its face, this looks like inflammation ramping up. Yet circulating cytokines remained reduced at the same time. The authors interpret this as evidence that transcriptional activation of immune-related pathways does not necessarily translate into systemic inflammatory output; it may instead reflect adaptive regulatory reprogramming. This distinction matters, because it separates genuine immunosuppression from a subtler recalibration of immune-metabolic networks, and it aligns with the well-established principle that cellular metabolism and immune cell behaviour are tightly intertwined.

The spleen told a very different story. Despite being the body’s central blood-filtering lymphoid organ, packed with T cells, B cells, macrophages and dendritic cells, and rich in CB2 cannabinoid receptors, the spleen showed remarkably modest transcriptional responses. Short-term treatment at the highest dose altered 40 genes, 38 of them downregulated, with the only significant enrichment involving lipid modification processes. Long-term treatment changed just two to four genes depending on dose. This muted splenic response, set against the liver’s dramatic remodeling, led the authors to a provocative conclusion: the systemic cytokine changes observed in blood are probably not driven primarily by classical immune organs, but rather by indirect regulation flowing from metabolically active tissues, with the liver acting as a kind of immunometabolic command centre.

Mechanistically, the findings fit CBD’s known multimodal pharmacology. Unlike THC, CBD has low affinity for the canonical CB1 and CB2 cannabinoid receptors and instead influences a scatter of molecular targets, including PPARγ, TRPV1 channels, adenosine signalling and redox-sensitive pathways, while inhibiting the transcription factor NF-κB, a master regulator of TNF-α and IL-1β expression. The early cytokine drops are consistent with NF-κB inhibition, while the delayed IL-6 decline may reflect a gradual attenuation of upstream inflammatory stimuli, since IL-6 production often sits downstream of IL-1β and TNF-α cascades. The lipid metabolism enrichment during long-term treatment echoes recent human cell studies showing that CBD can switch lipid mediator production toward inflammation-resolving species, and the authors’ own prior work found similar circadian and metabolic signatures in the kidneys of CBD-treated mice.

The study’s temporal dimension carries practical weight. Short-term exposure produced acute bioenergetic and stress-related transcriptional responses alongside rapid IL-1β and TNF-α suppression, whereas prolonged exposure shifted toward lipid handling, circadian regulation and broader immunometabolic pathways, with sustained IL-6 reduction. CBD’s high lipophilicity means it accumulates in lipid-rich, well-perfused tissues over repeated dosing, so the biological response evolves rather than simply intensifying. For anyone interpreting CBD experiments, or weighing its therapeutic potential, duration of exposure may matter as much as dose, and the two interact in ways that a single time point cannot capture.

The authors are careful about limitations. The pathways identified by RNA sequencing were not validated with targeted functional assays, bulk transcriptomics cannot distinguish changes within individual cell types from shifts in cellular composition, and only male mice were studied, leaving open the question of sex-dependent responses in endocannabinoid signalling and immunity. Still, the integrated picture is compelling: CBD lowered circulating pro-inflammatory cytokines while triggering strong, dose- and time-dependent transcriptional reprogramming in the liver and only limited changes in the spleen. Rather than acting as a blunt immunosuppressant, the compound appears to coordinate adjustments across mitochondrial bioenergetics, lipid metabolism, glucocorticoid pathways and circadian regulators such as REV-ERBα, nudging immune-metabolic networks toward balance. If that model holds up in functional studies and in both sexes, it could reshape how researchers think about CBD’s promise in inflammatory, autoimmune and metabolic disease.

Subject of Research: Effects of cannabidiol on systemic cytokines and liver and spleen transcriptomes in male mice

Article Title: Cannabidiol (CBD) differentially shapes systemic cytokines and transcriptomic profiles in the liver and spleen: insights from a male mouse model

Article References: Żurowski, J., Ocłoń, E., Jasielczuk, I., Szmatoła, T., Mizera-Szpilka, K., Semik-Gurgul, E., Sawicki, S., & Gurgul, A. (2026). Cannabidiol (CBD) differentially shapes systemic cytokines and transcriptomic profiles in the liver and spleen: insights from a male mouse model. Molecular Genetics and Genomics, 301(1), Article 200. https://doi.org/10.1007/s00438-026-02525-w

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02525-w

Keywords: cannabidiol, CBD, cytokines, transcriptomics, liver, spleen, immunometabolism, NF-kappaB, circadian rhythm, REV-ERBalpha, mouse model, inflammation

BPIFB1 is a member of the bactericidal permeability-increasing fold-containing family, a group of innate immune proteins whose members share a structural architecture evolved to bind lipids and engage microbial targets. The protein is abundantly expressed in the nasopharyngeal epithelium, the very tissue from which nasopharyngeal carcinoma arises, which makes its behavior in this cancer particularly consequential. According to the review, BPIFB1 is markedly downregulated in nasopharyngeal carcinoma tissues, and loss of its expression is associated with poor prognosis for patients. In other words, the more the molecule disappears from tumor cells, the worse the clinical outlook tends to be, a correlation that has prompted researchers to classify it as a tumor suppressor.

What makes the story compelling from a viral oncology standpoint is the mechanism behind that loss. The review highlights accumulating evidence that BPIFB1 is directly targeted and suppressed by EBV-encoded miR-BART4, one of the microRNAs the virus produces during latent infection. Epstein–Barr virus is known to maintain its long-term residence in infected cells in part by deploying a panel of BART microRNAs, which fine-tune both viral and host gene expression without provoking strong immune detection. By steering miR-BART4 at BPIFB1, the virus appears to strip the epithelium of one of its local sentinels, a maneuver that could undermine both the tissue’s barrier functions and its capacity to coordinate immune responses.

The authors frame BPIFB1 as a multi-node tumor suppressor, a description that captures the unusual breadth of its influence. Rather than acting through a single pathway, the molecule is implicated in regulating several of the classic hallmarks of cancer simultaneously. These include immune escape, the process by which tumor cells avoid recognition and destruction by cytotoxic lymphocytes; metastatic invasion, the acquisition of motile and tissue-infiltrating behavior that allows cancer cells to spread; and glycolytic reprogramming, the metabolic shift toward heightened glucose fermentation even in the presence of oxygen, known as the Warburg effect, which supports rapid proliferation.

The reach of BPIFB1 extends further still. The review identifies roles for the molecule in modulating radioresistance, a phenomenon of particular clinical relevance in nasopharyngeal carcinoma, where radiotherapy is a mainstay of treatment and tumor cells that withstand radiation drive treatment failure. BPIFB1 also appears to influence cell proliferation directly and to engage inflammation-associated signaling, including pathways centered on NF-kappaB, a transcription factor family that sits at the hub of inflammatory responses and is frequently co-opted in malignancy. Chronic inflammation in the tumor microenvironment is widely recognized as a driver of cancer progression, and a molecule capable of tempering those signals could in principle slow multiple aspects of tumor evolution at once.

An intriguing theme running through the review is that BPIFB1 does not behave identically in every tissue. The authors describe tissue-specific functional heterogeneity across multiple tumor types, citing evidence from breast, lung and gastric cancers in addition to nasopharyngeal carcinoma. This kind of context dependence is increasingly appreciated in cancer biology: a protein that suppresses growth in one epithelium may have more nuanced or even opposing effects elsewhere, depending on the local repertoire of interacting partners, signaling pathways and metabolic conditions. For researchers hoping to translate BPIFB1 findings into the clinic, this heterogeneity is a caution as well as an opportunity, since any therapeutic strategy would need to account for how the molecule behaves in the specific tissue being treated.

To situate these functional findings mechanistically, the review systematically summarizes the molecular structure of BPIFB1 and the regulatory mechanisms underlying its aberrant expression in cancer. The protein belongs to the PLUNC subfamily, which is expressed selectively in the upper airways and is thought to participate in the mucosal defense of these surfaces, contributing to the antimicrobial and anti-inflammatory properties of airway secretions. That lineage makes evolutionary sense of the molecule’s dual character: it is simultaneously an innate immune effector shaped for mucosal surveillance and, according to the evidence assembled by the Changsha team, a regulator of intracellular signaling circuits that tumors exploit for survival and spread.

Beyond cancer, the review casts a wider net, surveying recent advances in BPIFB1-related research across multi-system diseases. This broader framing reflects a growing recognition that innate immune molecules of the airway are not narrowly specialized anti-bacterial agents but participants in systemic biology, with potential relevance wherever epithelial barriers, mucosal immunity and inflammatory signaling intersect. The disease geography of nasopharyngeal carcinoma itself underscores the point, since the tight association between EBV and this tumor in specific populations suggests that host genetic and environmental factors modulating mucosal immunity may shape risk in ways that a single-virus, single-tissue perspective would miss.

On the translational front, the authors discuss BPIFB1’s potential as both a biomarker and a therapeutic target. As a biomarker, the molecule’s consistent downregulation in nasopharyngeal carcinoma and its association with poor prognosis suggest that measuring its expression could help stratify patients or track disease behavior. As a therapeutic target, the challenge is thornier, because restoring a suppressed tumor suppressor inside malignant cells is far more difficult than inhibiting an overactive oncogene. Yet the viral connection offers a conceptual foothold: if EBV-encoded miR-BART4 is the principal driver of BPIFB1 loss, strategies aimed at blunting that microRNA or counteracting its downstream effects could, in principle, reawaken the suppressed protein. The open-access review, which was published on 25 September 2026 and supported by the Project of Changsha Natural Science Foundation, does not claim such interventions exist today; it consolidates the mechanistic groundwork that would make them conceivable.

For a cancer that remains a major burden in Southern China and Southeast Asia, and for the broader field of virus-associated malignancy, the synthesis offered by Cai and colleagues is a reminder that the tumor microenvironment is shaped as much by what the immune system loses as by what the tumor gains. BPIFB1, a molecule of the airway’s first line of defense, emerges from this review as a lens through which viral manipulation, metabolic reprogramming, inflammatory signaling and immune evasion can be seen as a single connected story. Whether future work can convert that mechanistic insight into clinical tools, from prognostic assays to microRNA-targeted therapies, will depend on validating these roles across cohorts and disease settings, but the review makes a clear case that this underappreciated epithelial protein deserves a prominent place on the research agenda for nasopharyngeal carcinoma and beyond.

Subject of Research: Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1 in nasopharyngeal carcinoma

Article Title: Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1: mechanistic insights from nasopharyngeal carcinoma and implications for multi-system diseases

Article References: Cai, J., Jiang, F., Xiao, L., & Zhang, W. (2026). Tumor-suppressive and immunomodulatory roles of BPIFB1/LPLUNC1: mechanistic insights from nasopharyngeal carcinoma and implications for multi-system diseases. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04580-z

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04580-z

Keywords: BPIFB1, LPLUNC1, nasopharyngeal carcinoma, Epstein-Barr virus, miR-BART4, tumor suppressor, immunomodulation, glycolytic reprogramming, radioresistance, NF-kappaB, innate immunity, multi-system diseases

The molecule at the center of the study is CXCL9, a chemokine that acts as a beacon for effector CD8-positive T cells. Higher CXCL9 expression has been linked to better responses to immunotherapy across multiple cancer types, making it an attractive lever for converting cold tumors into inflamed ones. The problem is that the signaling circuitry governing CXCL9 production inside tumor cells is poorly understood. The two best-known inducers, the inflammatory cytokines interferon-gamma and TNF-alpha, activate the JAK-STAT and NF-kappaB pathways respectively, but these pathways crosstalk extensively with PI3K-AKT, MAPK and p53 signaling, all of which are frequently rewired in cancer. Untangling which of these interactions actually matter in a given tumor cell is a combinatorial nightmare.

The Eindhoven team’s solution was to build interpretable mechanistic models of the signaling network and then let an active learning algorithm decide which experiments to run next. They started by curating a prior knowledge network specific to CXCL9 regulation, drawing on literature and the DoRothEA database of transcription factors. The network spans five major pathways: JAK-STAT, NF-kappaB, PI3K-AKT, MAPK and p53, connected to upstream cytokines including IFN-gamma, TNF-alpha, IFN-alpha and EGF. This scaffold was converted into a set of logic-based ordinary differential equations, a formalism that turns qualitative wiring diagrams into continuous dynamical systems without requiring the detailed kinetic parameters that are usually unknown in cancer signaling. Each edge in the network carries an adjustable strength parameter, which makes the fitted models biologically interpretable rather than black boxes.

To train these models, the researchers worked with two pancreatic cancer cell lines, AsPC1 and BxPC3, chosen because reanalysis of the Genomics of Drug Sensitivity in Cancer database showed they respond very differently to drugs. They exposed the cells to the two cytokines alone and in combination, alongside five clinically relevant inhibitors targeting JAK, IKK, PI3K, MEK and RAS, and measured secreted CXCL9 protein using a bead-based immunoassay with flow cytometry readout. The results confirmed the central role of JAK-STAT signaling: the JAK inhibitor momelotinib strongly suppressed CXCL9 in both lines, while IFN-gamma drove robust induction. More intriguingly, the PI3K inhibitor taselisib and the MEK inhibitor trametinib boosted CXCL9 expression, especially when combined with dual cytokine stimulation, pointing to previously underappreciated regulatory routes.

The fitted models, ensembles of ten optimizations per cell line, reproduced the experimental data with striking accuracy, achieving Pearson correlations of 0.998 for AsPC1 and 0.995 for BxPC3. In silico knockout experiments, in which individual regulatory edges were systematically removed from the models, then revealed context-specific control points. Deleting the ERK-AR interaction reduced CXCL9 in BxPC3 but not AsPC1, while JAK-STAT1 and STAT1-CXCL9 knockouts affected only AsPC1. The NF-kappaB pathway emerged as the key mediator of synergy between IFN-gamma and TNF-alpha in both cell lines, whereas JAK-STAT interactions contributed to synergy specifically in BxPC3. Bootstrapped parameter comparisons quantified these differences, showing that eight pathway parameters were significantly stronger in BxPC3 while two, including IFNGR-JAK, were stronger in AsPC1, providing a mechanistic explanation for the cell lines’ divergent drug responses.

The truly novel element, however, was the active learning pipeline coupled directly to these mechanistic models. Active learning is well established in drug discovery, where it helps algorithms pick the most informative compounds to test next, but it had never before been integrated with mechanistic biological models of this kind. The workflow is elegantly cyclical: the model ensemble predicts CXCL9 responses for all untested perturbation conditions, an acquisition function selects a small batch of the most valuable candidates, those are measured in the wet lab, and the models are retrained on the expanded dataset. The researchers benchmarked four acquisition strategies on synthetic data: greedy sampling, which chases conditions predicted to produce the highest CXCL9; uncertainty sampling, which targets conditions where the model ensemble disagrees most; a hybrid of the two; and random selection as a baseline.

The benchmarking produced a clear and practically useful picture. Greedy and the hybrid strategy discovered 1.4 to 1.9 times more CXCL9-inducing conditions than random sampling after five rounds, but they also generated more false positives when too many conditions were added per round. Uncertainty sampling was less aggressive at finding hits but delivered the best model generalization, reaching a mean R-squared of 0.93 across all conditions, including unseen ones, significantly outperforming every other strategy. The choice of initial training set also mattered: a carefully hand-picked set of ten conditions yielded seventeen final hits on average compared with nine for the worst random set, though the pipeline proved capable of recovering from suboptimal starts. These findings offer concrete design guidance for anyone attempting similar iterative experiments under real resource constraints.

Crucially, the team then took the pipeline back into the laboratory, running two rounds of active learning with real measurements in both cell lines. The qualitative differences between strategies seen in silico reproduced experimentally. Greedy and hybrid selections produced the strongest CXCL9 induction, while uncertainty-guided choices explored a broader response range and most consistently shrank the model’s prediction uncertainty. One complication surfaced: some greedy-selected drug combinations, such as PI3K plus ERK inhibition, yielded lower CXCL9 than expected because the high cumulative drug concentration triggered apoptosis. A Caspase-3 assay confirmed strong negative correlations between cell death and chemokine secretion, and after correcting for apoptosis, the expected hierarchy of acquisition strategies re-emerged. This observation may also help explain conflicting reports in the literature linking CXCL9 to both favorable and unfavorable prognosis in pancreatic cancer, since cytotoxicity can mask genuine immunostimulatory effects.

The study’s broader significance lies in demonstrating that mechanistic modeling and active learning, usually pursued on separate tracks, can be fused into a data-efficient engine for biological discovery. The interpretable logic-ODE framework kept the experimental design grounded in prior biological knowledge, while the learning loop squeezed maximum information from minimal measurements. Among the most tantalizing findings were the frequent selections of AKT and p53 inhibitors by the hybrid strategy, both validated as CXCL9 inducers despite sitting outside the canonical JAK-STAT and NF-kappaB regulatory axes, suggesting that less-characterized signaling mechanisms may hold untapped potential for immunomodulation. The authors caution that predictions remain constrained by the structure of the prior knowledge network, and that future work could expand it with transcriptomic data, add multiplexed readouts such as PD-L1 or TGF-beta, and employ Bayesian parameter inference for better-calibrated uncertainty. But the proof of principle stands: rational, mechanism-driven design of combination therapies aimed at warming up cold tumors is no longer a distant aspiration, but an iterative workflow that a small lab can start running today.

Subject of Research: Active learning-guided mechanistic modeling of CXCL9 chemokine regulation in pancreatic cancer cells

Article Title: Active learning-guided mechanistic modeling reveals context-specific regulators of CXCL9 expression in pancreatic cancer cells

Article References: Wang, B.-R., Yelleswarapu, M., Descamps, L., & Eduati, F. (2026). Active learning-guided mechanistic modeling reveals context-specific regulators of CXCL9 expression in pancreatic cancer cells. Molecular Systems Biology, 22(8), 1360-1375. https://doi.org/10.1038/s44320-026-00221-w

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00221-w

Keywords: pancreatic cancer, CXCL9, active learning, mechanistic modeling, logic-ODE, immunotherapy, JAK-STAT, NF-kappaB, chemokines, cold tumors, drug combinations, systems biology

Tumor-associated macrophages, or TAMs, are among the most numerous immune cells in the hepatocellular carcinoma microenvironment, and their prevailing M2-like state is a principal reason why checkpoint inhibitors so often fall short. These macrophages secrete immunosuppressive cytokines such as interleukin-10 and transforming growth factor-beta, suppress cytotoxic T lymphocytes, and actively construct a barrier against immune attack. C5aR1, a G-protein-coupled receptor normally engaged by the complement fragment C5a during inflammatory responses, is highly expressed on these TAMs, making it an attractive point of intervention. Despite this biological logic, no C5aR1-targeted cancer therapy has ever been approved, largely because complement signaling is deeply woven into normal immune regulation and systemic blockade carries risks. The Chinese team hypothesized that LukS-PV, as a natural ligand for the human form of C5aR1, might offer a way to engage the receptor selectively on macrophages inside tumors and flip them from suppressive to inflammatory.

To test this idea rigorously, the researchers built an experimental system that could distinguish human C5aR1-dependent effects from murine biology. They established both subcutaneous tumor models and a hydrodynamic tail vein injection model that produces spontaneous liver tumors resembling immunotherapy-refractory hepatocellular carcinoma, using mice engineered to carry the human C5AR1 gene alongside wild-type controls. This design proved critical. When the animals were treated with LukS-PV, tumor growth was significantly suppressed in the humanized C5AR1 mice but not in the wild-type animals, a result that supports a mechanism specifically dependent on the human receptor. Macrophage depletion experiments further demonstrated that macrophages were essential mediators of the antitumor activity: when these cells were removed, the therapeutic benefit of LukS-PV largely disappeared, confirming that the drug’s effect runs through the macrophage compartment rather than through a direct action on tumor cells.

Single-cell RNA sequencing provided a high-resolution view of what LukS-PV actually does inside the tumor. The technique, which profiles gene expression in thousands of individual cells simultaneously, revealed that treatment reshaped the entire immune landscape of the tumor. Most strikingly, TAMs shifted away from their immunosuppressive M2-like phenotype toward inflammatory M1-like states, a transcriptional transformation accompanied by changes in the broader immune ecosystem. Flow cytometry and immunofluorescence staining of tumor tissue validated these findings in vivo, showing that the reprogrammed macrophage population was accompanied by increased infiltration of CD8-positive T cells, the cytotoxic lymphocytes responsible for killing cancer cells. Those T cells displayed enhanced effector activation and reduced markers of exhaustion, indicating that the therapy did not merely bring more immune cells into the tumor but restored their functional capacity to attack it.

The mechanistic core of the study lies in the signaling cascades that LukS-PV triggers downstream of C5aR1. Using transcriptomic and molecular analyses, the team showed that the bacterial protein inhibits C5aR1-dependent PI3K/AKT signaling within macrophages. This pathway, when active, supports the suppressive macrophage program, and its inhibition set off a cascade of downstream consequences. The researchers found that LukS-PV suppressed the GSK3β/CREB/IL-10 axis, a signaling route that drives production of interleukin-10, one of the most potent immunosuppressive cytokines in the tumor microenvironment. At the same time, treatment promoted NF-κB-associated inflammatory activation, steering macrophages toward a program characterized by pro-inflammatory gene expression. Chromatin immunoprecipitation followed by quantitative PCR was used to confirm the transcriptional wiring of this switch, linking receptor engagement to changes in the activity of specific transcription factors.

The reduction in TAM-derived interleukin-10 emerged as a pivotal consequence of this reprogramming. Interleukin-10 is a master regulator of immune suppression, and its abundance in liver tumors helps explain why CD8-positive T cells in hepatocellular carcinoma so often arrive exhausted and dysfunctional. When LukS-PV lowered IL-10 production by macrophages, the suppressive brake on T cells was released, allowing effector function to recover. The team confirmed this causally in vitro through macrophage-polarization assays and experiments using recombinant interleukin-10, which could partially restore the suppressive environment even after LukS-PV treatment. Enzyme-linked immunosorbent assays quantified the cytokine shift, and conditioned-medium experiments showed that the secreted products of reprogrammed macrophages were sufficient to influence T-cell behavior, establishing a paracrine mechanism by which macrophage reprogramming translates into T-cell revival.

Perhaps the most clinically consequential finding is that LukS-PV synergizes with immune checkpoint blockade. When the researchers combined LukS-PV with PD-1 antibodies in their models, the antitumor efficacy of the checkpoint inhibitor was substantially enhanced. This makes mechanistic sense: PD-1 blockade releases the inhibitory checkpoint on T cells, but it cannot help T cells that never become activated or that remain trapped in a suppressive microenvironment dominated by M2-like macrophages and interleukin-10. By converting the macrophage population from a suppressive to an inflammatory state, LukS-PV prepares the immunological ground on which checkpoint inhibitors operate. The combination addresses two complementary layers of immune dysfunction, the extrinsic suppression imposed by the tumor microenvironment and the intrinsic checkpoints operating on T cells themselves, offering a rationale for testing this pairing in patients whose tumors have proven refractory to immunotherapy alone.

The choice of LukS-PV as the targeting agent reflects an intriguing convergence of microbiology and cancer immunology. Panton-Valentine leukocidin is a bipartite toxin whose S component, LukS-PV, naturally recognizes human C5aR1 with high specificity. Because the receptor is a G-protein-coupled receptor expressed on myeloid cells, and because the human and mouse versions differ sufficiently that the ligand discriminates between them, the humanized mouse model was essential for demonstrating activity. The species specificity that complicates preclinical work also underscores a translational consideration: the mechanism demonstrated here is explicitly human C5aR1-dependent, which strengthens the argument for clinical relevance even as it highlights the limitations of standard murine models for evaluating such agents. The study’s use of both subcutaneous and orthotopic spontaneous models, including one designed to mimic immunotherapy-refractory disease, adds weight to the conclusion that the approach can work in a tumor microenvironment that closely resembles treatment-resistant human liver cancer.

Several questions will need answers before LukS-PV reaches the clinic. The dose, schedule, and safety profile of a molecule derived from a bacterial toxin require careful evaluation, particularly regarding off-tumor effects on myeloid cells that also express C5aR1 in inflamed tissues. The study was conducted under institutional ethics approval with rigorous monitoring of animal welfare, and the authors declare no competing interests, but the path from a humanized mouse model to a phase I trial in hepatocellular carcinoma will demand formal toxicology, pharmacokinetic characterization, and manufacturing development. Nevertheless, the conceptual advance is significant. The work identifies C5aR1 targeting as a promising translational strategy for overcoming immunotherapy resistance, and it demonstrates that a naturally occurring bacterial ligand can be repurposed as a macrophage-reprogramming agent rather than a cytotoxic one.

For patients with hepatocellular carcinoma, a disease that remains one of the leading causes of cancer mortality worldwide and for which immunotherapy benefits only a subset of those treated, the study offers a new molecular handle on the problem of resistance. By showing that the fate of tumor-associated macrophages can be deliberately redirected through a single receptor, and that this redirection unlocks the power of CD8-positive T cells and potentiates PD-1 blockade, Liu, Ma, Zhang and their colleagues have added a compelling entry to the growing list of strategies aimed at remodeling the tumor microenvironment. The idea that a component of one of medicine’s oldest adversaries, Staphylococcus aureus, might help convert cold liver tumors into hot ones is a reminder that the boundary between pathogen and medicine is often thinner than it appears, and that some of immunotherapy’s most useful tools may come from the most unexpected corners of biology.

Subject of Research: Targeting C5aR1 with LukS-PV to reprogram tumor-associated macrophages and improve immunotherapy in hepatocellular carcinoma

Article Title: LukS-PV targets human C5aR1 to reprogram tumor-associated macrophages and potentiate immunotherapy in hepatocellular carcinoma

Article References: Liu, G., Shi, L., Wei, Y., Yang, Z., Ding, P., Chang, W., Dai, Y., Nie, Z., Lu, B., Liu, X., Ma, X., & Zhang, S. (2026). LukS-PV targets human C5aR1 to reprogram tumor-associated macrophages and potentiate immunotherapy in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03837-w

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03837-w

Keywords: hepatocellular carcinoma, LukS-PV, C5aR1, tumor-associated macrophages, macrophage reprogramming, PD-1 blockade, immunotherapy resistance, IL-10, PI3K/AKT signaling, NF-kappaB, tumor microenvironment, liver cancer

Immunosenescence is far more than a simple decline in immune vigor. It is a sweeping remodeling of both the innate and adaptive arms of immunity, marked by a shrinking pool of naive T cells, an accumulation of exhausted memory cells, a narrowing of T-cell receptor diversity, and a chronic, low-grade inflammatory state often called inflammaging. These changes are closely tied to impaired immunometabolism, mitochondrial dysfunction, and shifts in key signaling networks, including the AMPK/mTOR axis, the NF-kappaB pathway, autophagy, and the NLRP3 inflammasome. Because no single molecular defect drives the process, the authors contend that a multi-target agent may be better suited to intervene than highly specific drugs aimed at one pathway at a time.

Berberine, an isoquinoline alkaloid extracted from plants such as Berberis vulgaris, has been used in traditional Chinese and Ayurvedic medicine for centuries. Modern pharmacology has mapped an impressive array of its molecular actions: it activates AMP-activated protein kinase (AMPK) partly by inhibiting mitochondrial respiratory complex I, suppresses mTOR signaling, modulates NF-kappaB-driven inflammation, promotes autophagy, and inhibits NLRP3 inflammasome activation. Each of these targets sits squarely at the intersection of the pathways that go awry during immunosenescence. Clinical evidence already supports berberine’s benefits in cardiometabolic disease, including type 2 diabetes, nonalcoholic fatty liver disease, and metabolic syndrome, and a phase 2 trial of berberine ursodeoxycholate showed proof of concept in patients with non-alcoholic steatohepatitis and type 2 diabetes.

The review assembles evidence from cellular, animal, and early human studies that speaks directly to immune aging. In cell culture, berberine suppresses gero-conversion, the transition from reversible cell-cycle arrest to full senescence, and protects cells from oxidative stress-induced senescence through AMPK activation, restoration of autophagic flux, and elevation of intracellular NAD+. In mice, the compound ameliorates cellular senescence and extends lifespan by regulating p16 and cyclin protein expression. In simpler organisms, berberine prolongs lifespan and stimulates locomotor activity in Drosophila melanogaster and extends lifespan in Caenorhabditis elegans through multi-target antioxidant effects and ROS-dependent activation of the PMK-1/SKN-1 stress-response pathway.

Particularly relevant to immune aging are berberine’s documented effects on inflammatory signaling. The compound inhibits LPS-induced inflammatory responses through the NF-kappaB pathway, blocks NLRP3 inflammasome activation in macrophages by triggering autophagy and regulating the mTOR/mitochondrial ROS axis, and reduces SASP-related inflammation through the RXRalpha/PPARgamma/NEDD4 pathway in models of atherosclerosis. It also modulates sirtuin 1 activity, a deacetylase implicated in immune cell longevity, and enhances innate antiviral defenses via the p38 MAPK pathway, with demonstrated anti-influenza activity in mice. Because the senescence-associated secretory phenotype, or SASP, is a major driver of chronic age-related inflammation, a drug that dampens SASP output while simultaneously supporting autophagy and mitochondrial quality control addresses several hallmarks of immune aging at once.

The review also highlights a newer generation of berberine derivatives engineered to overcome the parent compound’s most stubborn limitation: poor oral bioavailability. Berberine is poorly absorbed from the gut, relies partly on gut microbiota transformation into the intestine-absorbable form dihydroberberine, and is subject to efflux by P-glycoprotein. Chemists have responded with 8,8-dimethyldihydroberberine, 9-O-substituted and 9-N-alkyl derivatives, liposomal and nanoparticle formulations, and self-microemulsifying delivery systems, all of which improve absorption in animal or human studies. Some derivatives add entirely new capabilities: a 13-decyl berberine derivative has been described as a novel mitochondria-targeted antioxidant and potent inhibitor of ferroptosis, while tetrahydroberberrubine retards heart aging in mice by promoting PHB2-mediated mitophagy, and berberrubine-based mitorubin compounds improve mitochondrial function and protect against age-related cardiac dysfunction.

Yet the authors are careful to temper enthusiasm with critical caveats. Much of the immunosenescence-relevant evidence comes from in vitro work or from animal models whose immune systems differ substantially from aged humans. Direct clinical trials testing berberine specifically against immunosenescence biomarkers, such as T-cell receptor repertoire diversity, p16INK4a expression in peripheral blood T cells, senescence-associated beta-galactosidase in CD8+ T cells, or inflammatory aging clocks like iAge, have not been performed. Safety considerations also warrant attention: berberine inhibits cytochrome P450 enzymes in humans, raising drug-interaction risks, and it has been shown to alter blood levels of immunosuppressants such as cyclosporin A in transplant recipients. Its interaction with the adenine nucleotide translocator and complex I inhibition, while mechanistically central to AMPK activation, could be a double-edged sword in metabolically stressed immune cells.

To move the field forward, the review proposes a framework for future studies. The authors call for properly designed experiments in aged animal models that measure established immunosenescence biomarkers rather than generic inflammation endpoints, followed by carefully monitored human trials in older populations. They emphasize the value of modern immune-aging metrics, including single-cell immune aging clocks that capture inter-individual heterogeneity during infection and vaccination, and suggest that derivatives with improved bioavailability and mitochondrial targeting should be prioritized. Vaccine responsiveness in the elderly, which is notoriously blunted and linked to T-cell autophagy decline, is identified as a clinically meaningful outcome that a berberine-based intervention could plausibly improve.

The broader significance of the analysis lies in its reframing of an old herbal medicine as a systems-level geroprotector. Where most anti-aging pharmacology pursues single targets, berberine’s pleiotropy, acting simultaneously on energy sensing, inflammatory transcription, autophagy, inflammasome activity, and mitochondrial function, mirrors the interconnected nature of immune aging itself. Whether that pleiotropy translates into safe and measurable rejuvenation of the human immune system remains an open question, but the review provides the mechanistic rationale and the experimental roadmap needed to find out. If subsequent trials validate the promise, a compound once confined to traditional apothecaries could become a cornerstone of interventions designed to keep aging immune systems, and the aging populations they protect, healthier for longer.

Subject of Research: Evaluation of berberine and its derivatives as multi-target modulators of age-related immune system decline (immunosenescence).

Article Title: Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation

Article References: Zinovkin, R. A., Lyamzaev, K. G., Churov, A., Maltseva, O., & Wu, Z. (2026). Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation. Biogerontology, 27(5), Article 153. https://doi.org/10.1007/s10522-026-10504-2

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10504-2

Keywords: berberine, immunosenescence, aging, AMPK, mTOR, NF-kappaB, autophagy, NLRP3 inflammasome, inflammaging, mitochondria, berberine derivatives, geroprotection

The study began with chemical profiling. Using gas chromatography coupled to mass spectrometry, the researchers tentatively identified 63 distinct compounds in the lipophilic fraction of Liriope platyphylla root, abbreviated LLPR. This fat-soluble portion of the root contains molecules that differ from the polar steroids and polysaccharides typically emphasized in earlier work on the genus. The tentatively identified constituents include sterols and other lipophilic compounds such as stigmasterol, beta-sitosterol, and cycloartenol, molecules that have attracted attention in the pharmacological literature for their antioxidant and anti-inflammatory properties in their own right. By carefully cataloguing what the fraction actually contains, the team established a rational foundation for asking which biological targets those molecules might engage.

To move from a compound list to a mechanistic hypothesis, the researchers turned to network pharmacology, a computational strategy that maps the relationships between bioactive molecules, their predicted protein targets, and disease-associated biological pathways. When the 63 compounds were connected to known target proteins, a coherent picture emerged: LLPR constituents were predicted to associate with proteins central to the body’s oxidative stress and inflammatory responses. Among the most prominent hubs were NFE2L2, the gene encoding the transcription factor Nrf2; KEAP1, the sensor protein that holds Nrf2 in check; TLR4, a Toll-like receptor that triggers inflammatory signaling; NFKB1, a component of the NF-kappaB transcription complex; and PTGS2, the gene for cyclooxygenase-2, a key enzyme in inflammatory prostaglandin production.

These predicted targets are not arbitrary. The Nrf2-KEAP1 axis is widely regarded as the master regulatory system for cellular antioxidant defense. Under normal conditions, KEAP1 binds Nrf2 and directs it for degradation. When oxidative stress modifies KEAP1, Nrf2 escapes, accumulates, and travels to the nucleus, where it switches on a battery of cytoprotective genes, including the antioxidant enzymes catalase, glutathione peroxidase, and superoxide dismutase, as well as heme oxygenase-1, an enzyme with well-documented anti-inflammatory and antioxidant effects. Meanwhile, the TLR4 and NF-kappaB pathways represent the inflammatory side of the equation: activation of TLR4 by bacterial products such as lipopolysaccharide drives NF-kappaB into the nucleus, where it induces genes for inducible nitric oxide synthase, cyclooxygenase-2, and pro-inflammatory cytokines such as interleukin-1beta. A natural product fraction capable of modulating both arms of this network would, in principle, blunt the damaging amplification loop that links oxidative stress to chronic inflammation.

To test whether the predicted interactions were structurally plausible, the team performed molecular docking simulations. Docking computationally fits small molecules into the binding pockets of target proteins and scores how favorably they nestle there. The results suggested that LLPR constituents could bind to the oxidative stress- and inflammation-related proteins identified by the network analysis, lending structural credibility to the computational predictions. The authors are careful to stress, however, that docking and network pharmacology generate hypotheses rather than proof. The predicted molecular associations, they note, require direct mechanistic validation before any definitive claims about mechanism can be made. That candor distinguishes the study from less rigorous explorations in this field and sets a clear agenda for follow-up experiments.

The laboratory phase of the work proceeded in two stages. First, the researchers assessed the intrinsic antioxidant capacity of LLPR using cell-free assays, which measure a substance’s ability to neutralize reactive radicals in a test tube without the complication of living cells. LLPR exhibited measurable antioxidant capacity in these assays, confirming that at least part of its activity can be attributed to direct radical-scavenging chemistry, likely contributed by its lipophilic constituents.

The more biologically revealing experiments used RAW 264.7 macrophages, a widely used mouse immune cell line that models the inflammatory behavior of macrophages in tissue. The researchers stimulated the cells with lipopolysaccharide, a component of the outer membrane of Gram-negative bacteria that provokes a robust inflammatory and oxidative response, and then treated the cells with LLPR. The results were striking. LLPR restored the expression of catalase, an antioxidant enzyme that lipopolysaccharide had suppressed, and partially increased the expression of glutathione peroxidase and superoxide dismutase, two other first-line antioxidant enzymes. It also enhanced the expression of heme oxygenase-1, the inducible cytoprotective enzyme whose upregulation is a hallmark of Nrf2 pathway activation. Functionally, these changes mattered: LLPR reduced the accumulation of intracellular reactive oxygen species in the stressed macrophages, indicating that the enzyme-level changes translated into genuine protection against oxidative damage.

The anti-inflammatory side of the evaluation was equally encouraging. In the lipopolysaccharide-stimulated macrophages, LLPR attenuated the production of nitric oxide, a reactive molecule that contributes to inflammatory tissue damage, and reduced the expression of inducible nitric oxide synthase, the enzyme responsible for generating it. The fraction also lowered the expression of cyclooxygenase-2, the inducible enzyme that drives prostaglandin synthesis and is the target of common anti-inflammatory drugs, and it reduced levels of interleukin-1beta, a potent pro-inflammatory cytokine implicated in a broad range of inflammatory diseases. Taken together, the cellular data show that LLPR can simultaneously reinforce antioxidant defenses and restrain inflammatory signaling in a well-established model of inflammation, consistent with the dual action predicted by the computational analyses.

The broader significance of the work lies in both its methodology and its implications. Scientifically, the study exemplifies an increasingly popular integrated pipeline in natural product research: chemical profiling identifies what is in an extract, network pharmacology predicts what those constituents could do in the body, molecular docking tests whether the predictions are structurally feasible, and in vitro assays verify whether the predicted bioactivity is real in living cells. This chain of evidence is stronger than any single approach alone, and it offers a template for rapidly screening traditional medicinal plants whose complex chemistry has resisted conventional reductionist analysis. For Liriope platyphylla specifically, the study extends previous research, which has reported activities ranging from nerve growth factor induction to relief of atopic dermatitis symptoms and improved gastrointestinal motility, by systematically characterizing a lipophilic fraction that earlier work had largely overlooked.

The authors and observers alike caution that these are early findings. All of the biological results come from cell culture, and the cell-free and cellular assays, while informative, cannot capture the absorption, metabolism, distribution, and toxicity questions that determine whether a plant fraction will have useful effects in a living organism. The computational predictions linking LLPR constituents to Nrf2, KEAP1, TLR4, NF-kappaB, and cyclooxygenase-2 remain to be confirmed with direct biochemical experiments, such as binding assays and pathway-specific studies in cells and animal models. Human relevance is even further away. Nevertheless, the study provides a credible preliminary case that the lipophilic fraction of Liriope platyphylla root harbors antioxidant and anti-inflammatory activity, and it identifies specific molecular targets that future research can interrogate. For a root that traditional medicine has valued for centuries, the convergence of ancient use and modern systems-level analysis is a compelling signal that there may be real pharmacology waiting to be understood, one carefully validated mechanism at a time.

Subject of Research: Antioxidant and anti-inflammatory potential of a lipophilic fraction from Liriope platyphylla root

Article Title: Integrated chemical profiling, network pharmacology, molecular docking, and in vitro evaluation of the antioxidant and anti-inflammatory potential of a lipophilic fraction from Liriope platyphylla root

Article References: Truong, V.-L., Rarison, R. H. G., Bang, J.-H., Bae, Y.-J., Nitin, N., & Jeong, W.-S. (2026). Integrated chemical profiling, network pharmacology, molecular docking, and in vitro evaluation of the antioxidant and anti-inflammatory potential of a lipophilic fraction from Liriope platyphylla root. Food Science and Biotechnology. https://doi.org/10.1007/s10068-026-02291-w

Image Credits: AI Generated

DOI: 10.1007/s10068-026-02291-w

Keywords: Liriope platyphylla, antioxidant, anti-inflammatory, lipophilic fraction, network pharmacology, molecular docking, gas chromatography-mass spectrometry, Nrf2, NF-kappaB, macrophages, oxidative stress, natural products